Compare ESQ & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | DSGN |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 853.8M |
| IPO Year | 2017 | 2021 |
| Metric | ESQ | DSGN |
|---|---|---|
| Price | $123.60 | $11.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $120.33 | $15.25 |
| AVG Volume (30 Days) | 118.9K | ★ 989.5K |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 14.20 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.15 | N/A |
| Revenue Next Year | $39.09 | N/A |
| P/E Ratio | $88.12 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $90.57 | $3.76 |
| 52 Week High | $125.85 | $17.25 |
| Indicator | ESQ | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.70 | 37.64 |
| Support Level | $103.79 | $9.78 |
| Resistance Level | $124.95 | $11.88 |
| Average True Range (ATR) | 3.50 | 1.09 |
| MACD | 0.22 | -0.41 |
| Stochastic Oscillator | 75.10 | 0.74 |
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.